Search

Your search keyword '"Mélissande Cossutta"' showing total 11 results
Start Over Author "Mélissande Cossutta" Publication Year Range Last 3 years
11 results on '"Mélissande Cossutta"'

1. Supplementary Figure 1 from Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature

Author

Ilaria Cascone, Enrico Giraudo, José Courty, Anne Couvelard, Philippe Bouvet, Alberto Bardelli, Simona Lamba, Fabien Mongelard, Christopher Prochasson, Ksenya Shchors, Damien Destouches, Claire Houppe, Silvia Di Maria, Laure Caruana, Gilles Carpentier, Mélissande Cossutta, Federica Maione, and Maud-Emmanuelle Gilles

Abstract

N6L inhibits PDAC proliferation and migration

Published
2023
Full Text
View/download PDF

2. Supplementary Figure 2 from Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature

Author

Ilaria Cascone, Enrico Giraudo, José Courty, Anne Couvelard, Philippe Bouvet, Alberto Bardelli, Simona Lamba, Fabien Mongelard, Christopher Prochasson, Ksenya Shchors, Damien Destouches, Claire Houppe, Silvia Di Maria, Laure Caruana, Gilles Carpentier, Mélissande Cossutta, Federica Maione, and Maud-Emmanuelle Gilles

Abstract

NCL blocking antibody and Ncl deletion affects PDAC cell proliferation.

Published
2023
Full Text
View/download PDF

3. Supplementary Table 1 from Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature

Author

Ilaria Cascone, Enrico Giraudo, José Courty, Anne Couvelard, Philippe Bouvet, Alberto Bardelli, Simona Lamba, Fabien Mongelard, Christopher Prochasson, Ksenya Shchors, Damien Destouches, Claire Houppe, Silvia Di Maria, Laure Caruana, Gilles Carpentier, Mélissande Cossutta, Federica Maione, and Maud-Emmanuelle Gilles

Abstract

Proteome array analysis of angiogenic molecules secreted by ECs.

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 3 from Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature

Author

Ilaria Cascone, Enrico Giraudo, José Courty, Anne Couvelard, Philippe Bouvet, Alberto Bardelli, Simona Lamba, Fabien Mongelard, Christopher Prochasson, Ksenya Shchors, Damien Destouches, Claire Houppe, Silvia Di Maria, Laure Caruana, Gilles Carpentier, Mélissande Cossutta, Federica Maione, and Maud-Emmanuelle Gilles

Abstract

mPDAC orthopic model characterization.

Published
2023
Full Text
View/download PDF

5. Data from Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature

Author

Ilaria Cascone, Enrico Giraudo, José Courty, Anne Couvelard, Philippe Bouvet, Alberto Bardelli, Simona Lamba, Fabien Mongelard, Christopher Prochasson, Ksenya Shchors, Damien Destouches, Claire Houppe, Silvia Di Maria, Laure Caruana, Gilles Carpentier, Mélissande Cossutta, Federica Maione, and Maud-Emmanuelle Gilles

Abstract

Pancreatic cancer is a highly aggressive tumor, mostly resistant to the standard treatments. Nucleolin is overexpressed in cancers and its inhibition impairs tumor growth. Herein, we showed that nucleolin was overexpressed in human specimens of pancreatic ductal adenocarcinoma (PDAC) and that the overall survival significantly increased in patients with low levels of nucleolin. The nucleolin antagonist N6L strongly impaired the growth of primary tumors and liver metastasis in an orthotopic mouse model of PDAC (mPDAC). Similar antitumor effect of N6L has been observed in a highly angiogenic mouse model of pancreatic neuroendocrine tumor RIP-Tag2. N6L significantly inhibited both human and mouse pancreatic cell proliferation and invasion. Notably, the analysis of tumor vasculature revealed a strong increase of pericyte coverage and vessel perfusion both in mPDAC and RIP-Tag2 tumors, in parallel to an inhibition of tumor hypoxia. Nucleolin inhibition directly affected endothelial cell (EC) activation and changed a proangiogenic signature. Among the vascular activators, nucleolin inhibition significantly decreased angiopoietin-2 (Ang-2) secretion and expression in ECs, in the tumor and in the plasma of mPDAC mice. As a consequence of the observed N6L-induced tumor vessel normalization, pre-treatment with N6L efficiently improved chemotherapeutic drug delivery and increased the antitumor properties of gemcitabine in PDAC mice. In conclusion, nucleolin inhibition is a new anti-pancreatic cancer therapeutic strategy that dually blocks tumor progression and normalizes tumor vasculature, improving the delivery and efficacy of chemotherapeutic drugs. Moreover, we unveiled Ang-2 as a potential target and suitable response biomarker for N6L treatment in pancreatic cancer. Cancer Res; 76(24); 7181–93. ©2016 AACR.

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 5 from Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature

Author

Ilaria Cascone, Enrico Giraudo, José Courty, Anne Couvelard, Philippe Bouvet, Alberto Bardelli, Simona Lamba, Fabien Mongelard, Christopher Prochasson, Ksenya Shchors, Damien Destouches, Claire Houppe, Silvia Di Maria, Laure Caruana, Gilles Carpentier, Mélissande Cossutta, Federica Maione, and Maud-Emmanuelle Gilles

Abstract

N6L and angiogenic molecules regulation.

Published
2023
Full Text
View/download PDF

7. Supplementary Materials and Methods and Supplementary Figure Legends from Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature

Author

Ilaria Cascone, Enrico Giraudo, José Courty, Anne Couvelard, Philippe Bouvet, Alberto Bardelli, Simona Lamba, Fabien Mongelard, Christopher Prochasson, Ksenya Shchors, Damien Destouches, Claire Houppe, Silvia Di Maria, Laure Caruana, Gilles Carpentier, Mélissande Cossutta, Federica Maione, and Maud-Emmanuelle Gilles

Abstract

The Supplementary data contains the methods and the Supplementary figure legends

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 4 from Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature

Author

Ilaria Cascone, Enrico Giraudo, José Courty, Anne Couvelard, Philippe Bouvet, Alberto Bardelli, Simona Lamba, Fabien Mongelard, Christopher Prochasson, Ksenya Shchors, Damien Destouches, Claire Houppe, Silvia Di Maria, Laure Caruana, Gilles Carpentier, Mélissande Cossutta, Federica Maione, and Maud-Emmanuelle Gilles

Abstract

Stroma NCL inhibition increases pericyte coverage of tumor blood vessels.

Published
2023
Full Text
View/download PDF

10. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression

Author

Matteo Ponzo, Anais Debesset, Mélissande Cossutta, Mounira Chalabi-Dchar, Claire Houppe, Caroline Pilon, Alba Nicolas-Boluda, Sylvain Meunier, Fabio Raineri, Allan Thiolat, Rémy Nicolle, Federica Maione, Serena Brundu, Carina Florina Cojocaru, Philippe Bouvet, Corinne Bousquet, Florence Gazeau, Christophe Tournigand, José Courty, Enrico Giraudo, José L. Cohen, Ilaria Cascone, IMRB - I-BIOT/'Immunorégulation et Biothérapie' [Créteil] (U955 Inserm - UPEC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, CIC - Biotherapie - CHU Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Matière et Systèmes Complexes (MSC (UMR_7057)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), (le programme) Cartes d'identité des tumeurs (CIT), Ligue Nationales Contre le Cancer (LNCC), Università degli studi di Torino = University of Turin (UNITO), Candiolo Cancer Institute (IRCCS), École normale supérieure - Lyon (ENS Lyon), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'Oncologie médicale [CHU Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Henri Mondor, Gazeau, Florence, Matière et Systèmes Complexes (MSC), École normale supérieure de Lyon (ENS de Lyon), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Henri Mondor [Créteil]

Subjects
[SDV] Life Sciences [q-bio], PDAC, immune cells, nucleolin, vessels, Cancer Research, Oncology, [SDV]Life Sciences [q-bio]
Abstract

International audience; Background: The pancreatic ductal adenocarcinoma (PDAC) microenvironment is highly fibrotic and hypoxic, with poor immune cell infiltration. Recently, we showed that nucleolin (NCL) inhibition normalizes tumour vessels and impairs PDAC growth.Methods: Immunocompetent mouse models of PDAC were treated by the pseudopeptide N6L,which selectively inhibits NCL. Tumour-infiltrating immune cells and changes in the tumour microenvironment were analysed.Results: N6L reduced the proportion of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) and increased tumour-infiltrated T lymphocytes (TILs) with an activated phenotype. Low-dose anti-VEGFR2 treatment normalized PDAC vessels but did not modulate the immune suppressive microenvironment. RNAseq analysis of N6L-treated PDAC tumours revealed a reduction of cancer-associated fibroblast (CAF) expansion in vivo and in vitro. Notably, N6L treatment decreased IL-6 levels both in tumour tissues and in serum. Treating mPDAC by an antibody blocking IL-6 reduced the proportion of Tregs and MDSCs and increased the amount of TILs, thus mimicking the effects of N6L.Conclusions: These results demonstrate that NCL inhibition blocks the amplification of lymphoid and myeloid immunosuppressive cells and promotes T cell activation in PDAC through a new mechanism of action dependent on the direct inhibition of the tumoral stroma.

Published
2022
Full Text
View/download PDF

11. Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 14, 4265

Author

Matteo Ponzo, Anais Debesset, Mélissande Cossutta, Mounira Chalabi-Dchar, Claire Houppe, Caroline Pilon, Alba Nicolas-Boluda, Sylvain Meunier, Fabio Raineri, Allan Thiolat, Rémy Nicolle, Federica Maione, Serena Brundu, Carina Florina Cojocaru, Philippe Bouvet, Corinne Bousquet, Florence Gazeau, Christophe Tournigand, José Courty, Enrico Giraudo, José L. Cohen, and Ilaria Cascone

Subjects
Cancer Research, Oncology
Abstract

In the original publication [...]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results